In vitro interaction of fenretinide with plasma retinol-binding protein and its functional consequences
- PMID: 1386578
- DOI: 10.1016/0014-5793(92)81046-o
In vitro interaction of fenretinide with plasma retinol-binding protein and its functional consequences
Abstract
The synthetic retinoid fenretinide (4-HPR; N-[4-hydroxyphenyl] all-trans-retinamide) interacts with plasma apo-retinol-binding protein (RBP) to form a tight complex (K'd approximately 0.2 microM) which does not exhibit binding affinity to transthyretin (TTR). Therefore, a substantial modification of the retinol hydroxyl group does not appear to affect the interaction with RBP but does drastically interfere with the protein-protein recognition. The remarkable early reduction in plasma retinol level induced by fenretinide administration may be associated with the high binding affinity of this retinoid to RBP and to its interference with the RBP-TTR complex formation.
Similar articles
-
Secretion of vitamin A and retinol-binding protein into plasma is depressed in rats by N-(4-hydroxyphenyl)retinamide (fenretinide).J Nutr. 1992 Oct;122(10):1999-2009. doi: 10.1093/jn/122.10.1999. J Nutr. 1992. PMID: 1388202
-
Retinoid binding to retinol-binding protein and the interference with the interaction with transthyretin.Biochim Biophys Acta. 1996 May 2;1294(1):48-54. doi: 10.1016/0167-4838(95)00264-2. Biochim Biophys Acta. 1996. PMID: 8639713
-
Secretion of N-(4-hydroxyphenyl) retinamide-retinol-binding protein from liver parenchymal cells: evidence for reduced affinity of the complex for transthyretin.Int J Cancer. 1997 May 16;71(4):654-9. doi: 10.1002/(sici)1097-0215(19970516)71:4<654::aid-ijc23>3.0.co;2-a. Int J Cancer. 1997. PMID: 9178822
-
Plasma retinol-binding protein: structure and interactions with retinol, retinoids, and transthyretin.Vitam Horm. 2004;69:271-95. doi: 10.1016/S0083-6729(04)69010-8. Vitam Horm. 2004. PMID: 15196886 Review.
-
Interactions amongst plasma retinol-binding protein, transthyretin and their ligands: implications in vitamin A homeostasis and transthyretin amyloidosis.Biochim Biophys Acta. 2004 Dec 1;1703(1):1-9. doi: 10.1016/j.bbapap.2004.09.023. Biochim Biophys Acta. 2004. PMID: 15588697 Review.
Cited by
-
Advances and therapeutic opportunities in visual cycle modulation.Prog Retin Eye Res. 2025 May;106:101360. doi: 10.1016/j.preteyeres.2025.101360. Epub 2025 Apr 23. Prog Retin Eye Res. 2025. PMID: 40280538 Free PMC article. Review.
-
Long-term Fenretinide treatment prevents high-fat diet-induced obesity, insulin resistance, and hepatic steatosis.Am J Physiol Endocrinol Metab. 2009 Dec;297(6):E1420-9. doi: 10.1152/ajpendo.00362.2009. Epub 2009 Oct 13. Am J Physiol Endocrinol Metab. 2009. PMID: 19826103 Free PMC article.
-
The role of multimodal imaging and vision function testing in ABCA4-related retinopathies and their relevance to future therapeutic interventions.Ther Adv Ophthalmol. 2021 Dec 19;13:25158414211056384. doi: 10.1177/25158414211056384. eCollection 2021 Jan-Dec. Ther Adv Ophthalmol. 2021. PMID: 34988368 Free PMC article. Review.
-
Recent Advances in Age-Related Macular Degeneration Therapies.Molecules. 2022 Aug 10;27(16):5089. doi: 10.3390/molecules27165089. Molecules. 2022. PMID: 36014339 Free PMC article. Review.
-
Novel therapeutics for Stargardt disease.Graefes Arch Clin Exp Ophthalmol. 2017 Jun;255(6):1057-1062. doi: 10.1007/s00417-017-3619-8. Epub 2017 Mar 11. Graefes Arch Clin Exp Ophthalmol. 2017. PMID: 28285324 Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Research Materials
Miscellaneous